ACMR
ACM Research, Inc.
ACMR's outlook is improving, though it still trails on the overall score.
NVDA
NVIDIA Corporation
NVDA has the edge over ACMR overall, supported by stronger valuation and stronger fundamentals.
ACMR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Weak | |
| Healthy |
ACMR's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
ACMR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $24.47 | -51% |
| Forward | 18x | $49.88 | — |
| Fair | 26x | $41.77 | -16% |
| Current | 31x | $49.88 | — |
| Expensive | 74x | $119 | +139% |
Historical ranges are pointers, not guarantees.
ACMR's PE is in its fair range at 31x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over ACMR in the historical PE scenario, which offers more potential upside but is not a forecast.
ACMR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
ACMR has the edge over NVDA on the outlook, with more favorable profitability expectations.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
ACMR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.80 | +75% |
| Q3 2026 | $1.60 | -7.5% |
| Q2 2026 | $2.10 | +27% |
| Q1 2026 | $1.31 | -17% |
| Q4 2025 | $1.37 | -10% |
| Q3 2025 | $1.73 | +32% |
| Q2 2025 | $1.66 | +33% |
| Q1 2025 | $1.57 | +20% |
| Q4 2024 | $1.53 | +32% |
ACMR earned $1.60 per share over the past year, down 7.5% from the year before.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over ACMR on earnings, with more consistent year-over-year improvement.
ACMR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $367.7M | +37% |
| Q2 2026 | $292.9M | +36% |
| Q1 2026 | $231.3M | +34% |
| Q4 2025 | $244.4M | +9.4% |
| Q3 2025 | $269.2M | +32% |
| Q2 2025 | $215.4M | +6.4% |
| Q1 2025 | $172.3M | +13% |
| Q4 2024 | $223.5M | +31% |
ACMR's revenue has grown year over year for 18 quarters in a row: $368M last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +4.3 points |
| Q2 2026 | 17% | +2.3 points |
| Q1 2026 | 16% | +0.7 points |
| Q4 2025 | 9.4% | -10 points |
| Q3 2025 | 11% | -11 points |
| Q2 2025 | 15% | -3.8 points |
| Q1 2025 | 15% | -1.6 points |
| Q4 2024 | 20% | +6 points |
ACMR's operating margin was 15% last quarter, up 4.3 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over ACMR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over ACMR on profitability, with a higher operating margin.
ACMR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$95.6M | -$80M |
| Q2 2026 | -$71.5M | -$11.8M |
| Q1 2026 | -$51.7M | -$40.3M |
| Q4 2025 | $20.1M | -74% |
| Q3 2025 | -$15.6M | +$5M |
| Q2 2025 | -$59.6M | -223% |
| Q1 2025 | -$11.4M | +$23.6M |
| Q4 2024 | $77.2M | +$122.7M |
ACMR has burned cash in most quarters: −$199M over the past year, against −$10M the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over ACMR on cash generation, producing positive trailing cash flow while its opponent burns cash.
ACMR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.5% | +1.8M shares |
| 1 year | +7.6% | +5.2M shares |
| 3 years | +12% | +8.2M shares |
| 5 years | +13% | +8.2M shares |
| Available history | +28% | +16.2M shares |
ACMR has 74M diluted shares, up 7.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2020 | — |
| Q4 2019 | $2M |
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over ACMR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
ACMR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.9x | Net Cash |
| Q2 2026 | -4.0x | Net Cash |
| Q1 2026 | -4.0x | Net Cash |
| Q4 2025 | -3.8x | Net Cash |
| Q3 2025 | -5.6x | Net Cash |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.5x | Net Cash |
| Q4 2024 | -1.4x | Net Cash |
ACMR has the edge over NVDA on leverage, with a lower net debt burden relative to earnings.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
ACMR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.7 | Neutral |
| Stochastic | 13.7 | Oversold |
ACMR's weekly RSI is 40 (neutral) and its Stochastic is 14 (oversold).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
ACMR PE vs Technology Sector
| Metric | ACMR | Sector median | Relative |
|---|---|---|---|
| PE | 31x | 28x | 12% above |
| PE % | 54 | 35 | 19 pts above |
ACMR is trading at 31x earnings, a 12% premium to the Technology sector's median of 28x.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA has the edge over ACMR on valuation relative to its sector.
ACMR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $59.5 | 16% below |
| 20 week MA | $72.8 | 31% below |
| 50 week MA | $64.2 | 22% below |
| 100 week MA | $45.4 | 10% above |
| 200 week MA | $31.5 | 58% above |
ACMR has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
ACMR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.13 | $23.2 | +279% |
| 2021 | $23.2 | $25.9 | +11% |
| 2022 | $25.9 | $7.52 | -71% |
| 2023 | $7.52 | $19.5 | +160% |
| 2024 | $19.5 | $15.2 | -22% |
| 2025 | $15.2 | $40.6 | +167% |
| 2026 YTD | $40.6 | $49.9 | +23% |
ACMR has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.